Sugi Predict

Sugi Predict / Compounds / SCHEMBL2038445

SCHEMBL2038445

SCHEMBL2038445

OCc1ccc(C(F)(F)F)c(Br)c1

nearest known ligand 0.51

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ KIF11 P52732 1/20 0.51
▸ NOTUM Q6P988 2/20 0.45
▸ MBOAT4 Q96T53 1/20 0.39
▸ S1PR1 P21453 5/20 0.38
▸ RXRA P19793 2/20 0.38
▸ RXRB P28702 2/20 0.38
▸ RXRG P48443 2/20 0.38
▸ PDK2 Q15119 1/20 0.37
▸ AR P10275 1/20 0.36
▸ PTPN1 P18031 4/20 0.35
▸ PTPN2 P17706 1/20 0.35
▸ PTPN7 P35236 1/20 0.34
▸ DUSP3 P51452 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2094824 0.84 KIF11 (0.47) KIF11NOTUMS1PR1PDK2AR
SCHEMBL31337557 0.82 NOTUM (0.42) KIF11NOTUMMBOAT4RXRARXRB
SCHEMBL669905 0.82 NOTUM (0.42) KIF11NOTUMMBOAT4RXRARXRB
SCHEMBL1994099 0.81 KIF11 (0.56) KIF11NOTUMS1PR1RXRARXRB
SCHEMBL30368288 0.81 KIF11 (0.56) KIF11NOTUMS1PR1RXRARXRB
SCHEMBL14593088 0.80 KIF11 (0.38) KIF11NOTUMRXRARXRBRXRG
SCHEMBL12828072 0.80 NOTUM (0.49) KIF11NOTUMMBOAT4RXRARXRB
SCHEMBL4027912 0.80 LOXL2 (0.43) KIF11NOTUMMBOAT4RXRARXRB
SCHEMBL31142922 0.80 LOXL2 (0.43) KIF11NOTUMMBOAT4RXRARXRB
SCHEMBL3738325 0.79 PTPN1 (0.56) PTPN1PTPN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4587424-A1 YAP/TAZ-TEAD ONCOPROTEINS INHIBITORS Bridgene Biosciences, Inc. (US) 2025-07-23 — — EP disclosed
EP-4570313-A2 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2025-06-18 — — EP disclosed
CN-119894866-A YAP/TAZ-TEAD oncoprotein inhibitors 布里奇恩生物科学公司 2025-04-25 — — CN disclosed
WO-2025050636-A1 MACROCYCLIC PYRAZOLOPYRIMIDINE COMPOUND AND USE THEREOF 浙江养生堂天然药物研究所有限公司 2025-03-13 — — WO disclosed
CN-119552171-A Macrocyclic pyrazolopyrimidine compound and application thereof 浙江养生堂天然药物研究所有限公司 2025-03-04 — — CN disclosed
WO-2024059317-A1 YAP/TAZ-TEAD ONCOPROTEINS INHIBITORS BRIDGENE BIOSCIENCES, INC. (US) 2024-03-21 — — WO disclosed
CN-110198928-B Benzyloxy-pyridinyl-cyclopropanecarboxylic acid, pharmaceutical compositions and uses thereof 勃林格殷格翰国际有限公司 2023-08-29 — — CN disclosed
EP-4219477-A1 CYANOTRIAZOLE COMPOUNDS Otsuka Pharmaceutical Co., Ltd. (JP) 2023-08-02 — — EP disclosed
WO-2023055952-A1 NEUROTROPHIC TYROSINE RECEPTOR KINASE (NTRK) DEGRADING COMPOUNDS C4 THERAPEUTICS, INC. (US) 2023-04-06 — — WO disclosed
US-11583532-B2 Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (GOAT) inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2023-02-21 — — US disclosed
US-8173628-B2 Therapy for hormone sensitive diseases; side effect reduction; anticancer agents; osteoporosis; endometriosis; benign prostatic hyperplasia; cardiovascular disorders; acne NORTHEASTERN UNIVERSITY (US) 2012-05-08 — — US disclosed
US-8173628-B2 Therapy for hormone sensitive diseases; side effect reduction; anticancer agents; osteoporosis; endometriosis; benign prostatic hyperplasia; cardiovascular disorders; acne NORTHEASTERN UNIVERSITY (US) 2012-05-08 — — US disclosed
US-8173628-B2 Therapy for hormone sensitive diseases; side effect reduction; anticancer agents; osteoporosis; endometriosis; benign prostatic hyperplasia; cardiovascular disorders; acne NORTHEASTERN UNIVERSITY (US) 2012-05-08 — — US disclosed
WO-2011079102-A1 INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS SANOFI (FR) 2011-06-30 — — WO disclosed
WO-2011079102-A1 INDOLYL-PIPERIDINYL BENZYLAMINES AS BETA-TRYPTASE INHIBITORS SANOFI (FR) 2011-06-30 — — WO disclosed
US-20080166301-A1 Steroidal antiestrogens and antiandrogens and uses thereof NORTHEASTERN UNIVERSITY 2008-07-10 — — US disclosed
US-20080166301-A1 Steroidal antiestrogens and antiandrogens and uses thereof NORTHEASTERN UNIVERSITY 2008-07-10 — — US disclosed
US-20080166301-A1 Steroidal antiestrogens and antiandrogens and uses thereof NORTHEASTERN UNIVERSITY 2008-07-10 — — US disclosed
US-6642222-B2 Useful in hyperpolarizing cell membranes, opening potassium channels, relaxing smooth muscle cells, and inhibiting bladder contractions ABBOTT LABORATORIES 2003-11-04 — — US disclosed
US-20030055035-A1 Pyrano piperidino and thiopyrano compounds and methods of use ABBOTT LABORATORIES 2003-03-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055035-A1 Pyrano piperidino and thiopyrano compounds and methods of use KCNJ3, KCNJ6, KCNJ5 KIF11 1859/4885NOTUM 3349/4885MBOAT4 4399/4885
US-11583532-B2 Triazolopyrimidine derivatives for use as ghrelin o-acyl transferase (GOAT) inhibitors MBOAT4, GIPR, MTTP KIF11 4536/4885NOTUM 835/4885MBOAT4 1/4885
US-20080166301-A1 Steroidal antiestrogens and antiandrogens and uses thereof NR5A1, SHBG, AR KIF11 4133/4885NOTUM 1782/4885MBOAT4 1216/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.